Dilek Telci Temeltas

Research Projects

• T.C. MINISTRY OF DEVELOPMENT RESEARCH INFRASTRUCTURE SUPPORT GRANT Project “Cellular and Gene Therapies Research, Development and Production Center”, Researcher, 12.12.2016-12.12.2019.
• TÜBİTAK 1003 Project “Development of Poly(2-ethyl-2-oxazoline) (PEtOx) Based Multifunctional Carrier Systems for Treatment and Diagnosis of Prostate and Breast Cancer”, Work package leader, 15.07. 2014-15.01.2018.
• TÜBİTAK 1001 Project "Anti-tumor effects ABT-737 and RAD-001(Everolimus) combination chemotherapy on Renal Cell Carcinoma in a murine RenCA model”. Project leader, 15.10. 2014-15.10.2017.
• Marie-Curie Action FP-7 People-2011 ITN “Transglutaminase in disease; a novel therapeutic target?”, Work package leader,, 1.11.2011-1.11.2015.
• Industry and Trade Industry Thesis Program (SAN TEZ) “Development and industrial production of new microbial formulations in mosquito control”, Researcher, 01.03.2011-30.08.2013.
• TÜBİTAK 1001 Project “In Vitro Effects Of Sambucus Nigra, Sambucus Ebulus And Cistus Laurifolius Leaves Whıch Are Used In Tradıtıonal Medıcıne On Several Inflammatory Parameters And Nf-Κb Sıgnallıng Pathway”, Researcher, 15.10.2010-15.10.2012.
• TÜBİTAK 1002 Project “Importance of tissue transglutaminase and secretory phospholipase A2 interaction in the formation of atherosclerotic plaque” Project leader, 01.05.2010-01.05-2011.
• TÜBİTAK 3501 Project ““Role of tissue transglutaminase induced integrin trafficking in kidney cancer metastasis”, Project leader 15.03.2010-15.03.2012.
• TÜBİTAK 1001 Project “Nitic oxide induced tissue transglutaminase and TGFβ-1 modulation; molecular mechanisms in fibrogenesis and wound healing.” Project leader, 01.07.2005-01.01.2008.

Publications

1. İ. Kurt-Celep, E. Celep, S. Akyüz, Y. İnan, T.H. Barak, G. Akaydın, D. Telci, E. Yesilada. “Hypericum olympicum L. recovers DNA damage and prevents MMP-9 activation induced by UVB in human dermal fibroblasts”. J Ethnopharmacol.,  246:112202, 2020.
2. O. Rencuzogulları, P.O. Yerlikaya, A.Ç. Gürkan, E.D. Arısan, D. Telci. “Palbociclib, a  selective CDK4/6 inhibitor, restricts cell survival and epithelial-mesenchymal transition in Panc-1 and MiaPaCa-2 pancreatic cancer cells.” J Cell Biochem, 121 (1): 508-523, 2020.
3. A. H. Nayman, H. Siginc, I. E. Zemheri, F. Yencilek, A. Yıldırım, D. Telci. “Dual-Inhibition of mTOR and Bcl-2 Enhances the Anti-tumor Effect of Everolimus against Renal Cell Carcinoma In Vitro and In Vivo.”. JOURNAL OF CANCER, 10(6):1466-1478, 2019.
4. U. C. Oz, B.U. Kucukturkmen, U. B. Ozkose, S. Gulyuz, B.Z. Bolat, D. Telci, F. Sahin, O. Yılmaz, A. Bozkir “Design Of Colloidally Stable And Non-Toxic Petox-Based Polymersomes For Cargo Molecule Encapsulation” ChemNanoMat 5(6):766-775, 2019.
5. E. Nezir, B. Ulukan & D. Telci, “Transglutaminase 2: The Maestro Of The Oncogenic Mediators In Renal Cell Carcinoma”. Medical Sciences6;7(2). pii: E24, 2019.
6. Dogan, S. Demirci, D. Telci, S. Canikyan, M. Kongur, B. Dede & F. Sahin, Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer, Internatıonal Urology And Nephrology, 50(2):247-25, 2018.
7. Kara, N. Öztürk, G. Esendagli, U. U. Köse, S. Gülyüz, Ö. Yılmaz, D. Telci, A. Bozkır, İ. Vural. “Development Of Novel Self-assembled Polymeric Micelles From Partially Hydrolysed Poly(2-ethyl-2-oxazoline)-co-pei-b-pcl Block Copolymer As Non-viral Vectors For Plasmid Dna In Vitro Transfection”. Artificial Cells Nanomedicine Biotechnology, 46(sup3):S264-S273, 2018.
8. S. Gulyuz, U.U. Ozkose, P.Kocak, D.Telci, O. Yilmaz, M.A. Tasdelen. “In-vitro cytotoxic activities of poly(2-ethyl-2-oxazoline)-based amphiphilic block copolymers prepared by CuAAC click chemistry.” Express Polymer Letters, 12 (2): 146-158, 2018.
9. A.Doğan, S.Demirci, D.Telci, S.Canikyan, M.Kongur, B.Dede, F.Şahin. “Anticancer activity of Schiff base-Poloxamer P85 combination against kidney cancer.” Int Urol Nephrol., 50(2):247-255, 2018.
10. Y.Bagatur, A.Z. Ilter Akulke, A.Bihorac, M.Erdem, D.Telci. “Tissue Transglutaminase expression is necessary for adhesion, metastatic potential and cancer stemness of renal cell carcinoma.” Cell Adh Migr. 12(2):138-151, 2018.
11. İ.A.Balkan, A.Z. İlter Akülke, Y.Bağatur, D.Telci, A.C.Gören, H.Kırmızıbekmez, E.Yesilada. "Sambulin A and B, non-glycosidic iridoids from Sambucus ebulus, exert significant in vitro anti-inflammatory activity in LPS-induced RAW 264.7 macrophages via inhibition of MAPKs's phosphorylation." J Ethnopharmacol., 206:347-352, 2017.
12. S.Demirci, A. Doğan, N.Başak Türkmen, D. Telci, A.B. Çağlayan, M.Ç. Beker, E.Kiliç, F.Özkan, B.Dede, F.Şahin. "Poloxamer P85 increases anticancer activity of Schiff base against prostate cancer in vitro and in vivo." Anticancer Drugs, 28(8):869-879, 2017.
13. A.Doğan, D.Telci, Prostat Kanseri Kök Hücresi, Türkiye Klinikleri Üroloji Özel Dergisi; 10(2):77-81, 2017.
14. P.Kocak, S.Canikyan, M.Batukan, R.Attar, F.Sahin, D.Telci. “Comparison of enzymatic and non-enzymatic isolation methods for endometrial stem cells.” Turk J Biol., 40 (5): 1081-1089, 2016.
15. S.Demirci, A.Dogan, N.B.Türkmen, D.Telci, A.A.Rizvanov, F. Şahin. “Schiff base-Poloxamer P85 combination demonstrates chemotherapeutic effect on prostate cancer cells in vitro.” Biomed Pharmacother., 86:492-501, 2017.
16. A.Dogan, S.Demirci,  N.B.Türkmen, A.B.Caglayan, S.Aydın, D.Telci, E.Kılıc, K.Sahin, C.Orhan, M.Tuzcu, A.I.Ekici, F.Sahin. “Schiff base-poloxamer P85 combination prevents prostate cancer progression in C57/Bl6 mice”. Prostate., 76(15):1454-63, 2016.
17. S.Demirci, A.Dogan, N.Basak, D.Telci, B.Dede, C. Orhan C, M.Tuzcu, K.Sahin, F.Sahin, N.Şahin, İ.H.Özercan, Şahin F “A Schiff base derivative for effective treatment of diethylnitrosamine-induced liver cancer in vivo.” Anticancer Drugs., 26(5): 555-64, 2015.
18. S.Erdem, G.Yegen, D.Telci, I.Yildiz, T.Tefik, H.Issever, I.Kilicaslan, O.Sanli, “The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma.” World J Urol., 33 (10), 1553-1560, 2015.
19. A.Dogan, N.Basak , S.Demirci, D.Telci, B.Dede, M.Tuzcu, I.H. Ozercan, K.Sahin, F.Sahin “A novel Schiff base derivative for effective treatment of azoxymethane induced colon cancer.”, Int. J Pharm. Sci. and Res., 5(8): 3544-3550, 2014.
20. E. Aysan, F. Sahin, D. Telci, M. Erdem, M. Muslumanoglu, E. Yardımcı, H. Bektasoglu “Mechanism of body weight reducing effect of oral boric Acid intake.” Int J Endocrinol., 2013:91465; 2013.
21. E. Aysan, O.F. Bayrak, E. Aydemir, D. Telci, F. Sahin, C. Yardimci, M. Muslumanoglu. “Cancer Preventive Effects of Whole Cell Type Immunization against Mice Ehrlich Tumors.” Asian. Pac. J. Cancer. Prev., 14(6):3515-9, 2013.
22. M. Erdem, S. Erdem, O.Sanli, H. Sak, I. Kilicaslan, F. Sahin, D.Telci “Up-regulation of TGM2 with ITGB1 and SDC4 is important in the development and metastasis of renal cell carcinoma.” Urol Oncol., 32(1):25.e13-20, 2013.
23. K.Sarıca, H.Aydin, F.Yencilek, D.Telci, B.Yilmaz “Human umbilical vein endothelial cells accelerate oxalate-induced apoptosis of human renal proximal tubule epithelial cells in co-culture system which is prevented by pyrrolidine dithiocarbamate. ” Urol Res. 40(5):461-6, 2012.
24. O.Tanriverdi, D.Telci, M.Aydin, I.D.Ekici ID, C. Miroglu C, K.Sarıca “Hyperoxaluria-induced tubular ischemia: the effects of verapamil and vitamin E on apoptotic changes with an emphasis on renal papilla in rat model.” Urol Res.(ISI), 40(1):17-25, 2012.
25. E.Aysan, F.Sahin, D.Telci, M.E. Yalvac, S.H.Emre, C.Karaca, M.Muslumanoglu “Body weight reducing effect of oral boric acid intake” Int J Med Sci., 8(8):653-8, 2011.
26. D.Telci, A.U.Dogan, E.Ozbek, E.C.Polat, A.Simsek, S.S.Cakir, H.O.Yeloglu, F.Sahin, "KLOTHO Gene Polymorphism of G395A Is Associated with Kidney Stones", American Journal of Nephrology, 33(4):337-43, 2011.
27. Z.Wang, D.Telci, M.Griffin, "Importance of syndecan-4 and syndecan-2 in osteoblast cell adhesion and survival mediated by a tissue transglutaminase-fibronectin complex", Experimental Cell Research, 317(3):367-81, 2011.
28. Z.Wang Z., R.J.Collighan, S.R.Gross S.R., E.H.Danen, G.Orend, D.Telci, M.Griffin, "RGD-independent Cell Adhesion via a Tissue Transglutaminase-Fibronectin Matrix Promotes Fibronectin Fibril Deposition and Requires Syndecan-4/2 and alpha 5 beta 1 Integrin Co-signalin", The Journal of Biological Chemistry, 285(51):40212-29, 2010.
29. D.Telci, R.J.Collighan, H.Basaga, M.Griffin M, "Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide", The Journal of Biological Chemistry, 284(43):29547-58, 2009.
30. E.D.Arısan, O.Kutuk, T.Tezil, C.Bodur, D.Telci, H.Basaga, "Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells", Breast Cancer Research and Treatment, 119(2):271-81, 2010.
31. D.Telci, Z.Wang, X.Li, E.A.Verderio, M.J.Humphries, M.Baccarini, H.Basaga, M.Griffin, "Fibronectin-TG2 matrix rescues RGD-impaired cell adhesion through Syndecan-4 and β1 Integrin co-signaling", The Journal of Biological Chemistry, 283(30):20937-47, 2008.
32. D.Telci, M.Griffin M, "Tissue transglutaminase (TG2)-a wound response enzyme", Frontiers in Bioscience, 11:867-82, 2006.
33. E.A.Verderio, D.Telci, A.Okoye, G.Melino, M.Griffin, "A novel RGD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis", The Journal of Biochemistry, 278(43):42604-14, 2003.

Book Chapters:

1. F.Şahin, D.Telci, Book Title: Güncel Biyoteknoloji ve Uygulamaları, Chapter Title: Modern Biyoteknoloji Ürünlerinin İnsan ve Çevre Sağlığı Üzerine Etkileri, page: 535-548, Kayseri Türkiye, Erciyes Üniversitesi Yayınları, 2017.
2. D.Telci, Y.Özlük, Ö.Şanlı, Editör: A.Yıldırım, Book Title: Böbrek Tümörlerinde Genetik ve Histopatoloji Konularının Güncellenmesi, Chapter Title: Böbrek Tümörlerinde Genetik ve Histopatoloji Konularının Güncellemesi, page:1-13, İstanbul, Türkiye, TÜD/TÜRK ÜROLOJİ AKADEMİSİ YAYINI NO:4, 2016.
3. D. Telci, A.Z.İlter, M. Erdem, Editör K.Turksen, Book Title: Stem Cells: Current Challenges and New Directions, Chapter Title: Stem Cells in Wound Healing, 175-197pp., Humana Press, Springer New York Heidelberg Dordrecht London, 2013.
4. F.Şahin, D.Telci, Book Title: Modern Biyoteknoloji ve Uygulamaları, Chapter Title: Genetik Yapısı Değiştirilmiş Organizmalar), page:143-153, Kayseri Türkiye, Erciyes Üniversitesi Yayınları, 2010.
5. D.Telci, A.Özalpan, N.Palavan Ünsal, Book Title: Genomik Uygulamalar, Chapter Title: Mikro array analizleri, 27-37 pp., İstanbul, Türkiye, T.C. İstanbul Kültür Üniversitesi Yayınları, 2008.

Other Scientific Activities:

• D. Telci, Molecular Pathways in RCC, B2B Renal Cancer meeting, Société Internationale d’Urologie, 8th Eurasian Uro-oncology Congress, June 28, 2016, Tbilisi, Georgia, Key Note Speaker. Recipient of “Best Science Award”.
• D.Telci, Bilim ve Akademi Dünyasının Lider ve Girişimci Kadınları, women's entrepreneurship day, WED TURKEY, 19 Kasım 2016 (Speaker).
• D. Telci, Prostate Cancer Stem Cell, B2B–Prostate Cancer meeting, Société Internationale d’Urologie, İstanbul Medipol University September 3, 2016, Istanbul (Key Note Speaker).
• D. Telci, Ne yediğimi Biliyorum, 8. Ataşehir Bilim Şenliği, Ataşehir Belediyesi, 25 Mayıs 2013 (Speaker).
• D.Telci, Böbrek kanserinde genetik mekanizmalar, BÖBREK TÜMÖRÜ GÜNCELLEME KURSU, Türk Üroloji Derneği, 28 Kasım, 2015 (Key Note Speaker).
• Kök Hücre ve Gen Terapi Sempozyumu, 25-28 Kasım 2013, Yeditepe Üniversitesi, Organization Committee Member.
• 2. International Congress on Stem Cell and Cellular Therapies. Turkey, 2015, Organization Committee Member.